arrow
S

Stephen L. Chan

Prince of Wales Hospital
H指数:84
被引数:3.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin–gemcitabine–durvalumab in advanced biliary tract cancers

从临床试验疗效到真实世界有效性:评估顺铂-吉西他滨-度伐利尤单抗在晚期胆道癌中的普适性

2026-11-040
PRE
Prognostic Role of Adverse Events in a Worldwide Population of Patients with Biliary Tract Cancer Treated with Chemo-Immunotherapy

胆道癌患者接受化疗免疫疗法治疗后不良事件预测作用的全球人群研究

Cancers
IF4.4
2026-09-100
OA
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
Radiation-induced Lymphopenia is Associated with Survival in Patients with Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy

辐射诱导的淋巴细胞减少与接受立体定向体部放射治疗的患者肝癌生存率相关

2025-12-110
OAAI
Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

IIIb期SIERRA研究早期安全性结果:度伐利尤单抗和特瑞普利单抗作为不可切除肝细胞癌且预后不良患者的一线治疗方案。

2025-12-010
OA
Specific indicators of unsuitability for transarterial chemoembolisation in patients with intermediate-stage hepatocellular carcinoma according to thresholds of tumour burden and liver function as judged by survival benefit over sorafenib

根据肿瘤负荷和肝功能阈值判断的中位生存期获益超过索拉非尼的中期肝细胞癌患者经动脉化疗栓塞术不适宜的特异性指标

2025-12-010
PRE
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study

卡瑞利珠单抗联合瑞戈非尼 versus 索拉非尼作为不可切除肝细胞癌的一线治疗(CARES-310):一项随机、开放标签、国际性、III期研究的最终分析

2025-11-240
PRE
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma

野生型KRAS的激活驱动干扰素介导免疫的逃避以及对免疫治疗的耐药性在肝细胞癌中。

2025-11-110
OAAI